RecruitingPHASE2, PHASE3NCT07499700

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Studying Idiopathic steroid-sensitive nephrotic syndrome

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bio-Thera Solutions
Principal Investigator: hui Ming Zhao
Peking University First Hospital
Intervention: BAT4406F(drug)
Enrollment: 192 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2025 – 2030

Study locations (1)

Peking University First Hospital, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07499700 on ClinicalTrials.gov

Other trials for Idiopathic steroid-sensitive nephrotic syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT03949972
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
Prof. Dr. Paul Brinkkoetter

See all trials for Idiopathic steroid-sensitive nephrotic syndrome →

← Back to all trials